Roche's VENTANA MMR RxDx Panel Secures IVDR Approval As Companion Diagnostic Across Five Cancer Types, Six Indications For Keytruda, Imfinzi, Lynparza And Jemperli
هوفمان-لا روش
هوفمان-لا روش ADR
ROCHE HOLDINGS AG
ROCHE HOLDINGS AG RHHBF | 0.00 | |
ROCHE HOLDINGS AG RHHBY | 0.00 | |
ROCHE HOLDINGS AG RHHVF | 0.00 |
- Used as a predictive biomarker, the first-of-its-kind VENTANA MMR RxDx Panel helps identify cancer patients eligible for treatment with certain precision oncology therapies
- By evaluating a panel of MMR proteins in tumours, the test provides clinicians with a standardised testing option to determine mismatch repair (MMR) status
- This IVDR approval expands the companion diagnostic's label to include five cancer types and six indications